Gallium-67 scan in clinical assessment of cancer
From symposium on staging and prognosis of Hodgkin's disease; Buffalo, NY (22 Mar 1973). By 1 April 1973, 770 patients with malignancy were studied using Gallium-67 (/sup 67/Ga) citrate radioisotopic scanning at the Clinical Center, National Institutes of Health. Of these, 21 had brain tumors, 19 (90%) of which concentrated /sup 67/Ga. Forty-four patients with melanoma had 54% of proven sites visualized on /sup 67/Ga scan (masses larger than 2 cm were detected in 75% of the sites). Ewing's sarcoma was studied in 15 patients with /sup 67/Ga scanning and all 15 primary tumors were visualized. Thirty-two of 43 scans performed on 30 patients with acute leukemia were abnormal. Sites of leukemic involvement in bone marrow and as myeloblastomas in soft tissue contained high levels of /sup 67/Ga. Patients with untreated Hodgkin's disease were abnormal in 90% of cases on /sup 67/Ga scan with 70% of proven sites of involvement being detectable. Sixty percent of non-Hodgkin's lymphoma sites were detected on /sup 67/Ga scans. Approximately 85% of anatomic sites involved with lung cancer were detected on scan. /sup 67/Ga citrate whole body scanning has proven to be useful in diagnosing and staging a wide variety of human tumors. The /sup 67/Ga study is most reliable when positive findings are recorded, but should be approached with caution when the findings are negative. (auth)
- Research Organization:
- National Institutes of Health, Bethesda, MD
- Sponsoring Organization:
- USDOE
- NSA Number:
- NSA-29-018740
- OSTI ID:
- 4339434
- Journal Information:
- J. Surg. Oncol., v. 5, no. 6, pp. 529-538, Conference: Symposium on staging and prognosis of Hodgkin's disease, Buffalo, NY, 22 Mar 1973; Other Information: Orig. Receipt Date: 30-JUN-74
- Country of Publication:
- Country unknown/Code not available
- Language:
- English
Similar Records
Clinical usefulness of /sup 67/Ga scanning in the malignant lymphomas
$sup 67$Ga scintigraphy in acute leukemia